Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105768702 | 10576870 | 2 | F | 20160711 | 20141111 | 20160712 | EXP | TW-BRISTOL-MYERS SQUIBB COMPANY-21556733 | BRISTOL MYERS SQUIBB | 74.00 | YR | M | Y | 0.00000 | 20160712 | OT | TW | TW |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 105768702 | 10576870 | 1 | PS | WARFARIN SODIUM. | WARFARIN SODIUM | 1 | Unknown | THERAPY START: 1 MONTH | Y | 9218 | 1.25 | MG | QD | ||||||
| 105768702 | 10576870 | 2 | I | QUETIAPINE. | QUETIAPINE | 1 | Unknown | THERAPY START: FOR 3 YEARS | Y | 0 | 400 | MG | QD | ||||||
| 105768702 | 10576870 | 3 | I | QUETIAPINE. | QUETIAPINE | 1 | Y | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 105768702 | 10576870 | 1 | Deep vein thrombosis |
| 105768702 | 10576870 | 2 | Vascular dementia |
| 105768702 | 10576870 | 3 | Delusion |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 105768702 | 10576870 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 105768702 | 10576870 | Drug interaction | |
| 105768702 | 10576870 | International normalised ratio increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |